| Project Title | Anti-Tumor Necrosis Factor (TNF) Utilization Among Pregnant Women |
| Date Posted | Wednesday, December 20, 2017 |
| Project ID | cder_mpl1r_wp057_nsdp_v01 |
| Status | Complete |
| Deliverables | |
| Description | This report contains estimates of use of five tumor necrosis factor (TNF)-alpha inhibitors, etanercept, adalimumab, infliximab, certolizumab, and golimumab, that occurred during a pregnancy resulting in a liveborn delivery, or within 90 days prior to the estimated start of pregnancy. The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2004 to September 30, 2015. This request was distributed to 16 Data Partners on June 27, 2017. |
| Medical Product | adalimumab certolizumab etanercept golimumab infliximab tumor necrosis factor (TNF) alpha inhibitor |
| Population / Cohort | Females 15-54 years of age |
| Time Period | January 1, 2004 - September 30, 2015 |
| Assessment Type | Exploratory Analyses |
| Study Type | Modular Program |
| Data Sources | Sentinel Distributed Database (SDD) |
| FDA Center | CDER |
